Ocular Therapeutix announced it plans to accelerate its intended New Drug Application (NDA) for AXPAXLI (OTX-TKI) for the ...
The US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to EyeYon Medical for its US clinical study of EndoArt, which is currently designated by the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback